Caffeine

CHEMBL113 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

194.2 g/mol

LogP

-0.1

Phase

4

A widely consumed methylxanthine stimulant that blocks adenosine receptors in the brain, promoting wakefulness and alertness. Medically, it is used in combination with analgesics for headaches, as a respiratory stimulant in premature infants, and is being studied for neuroprotective effects in conditions like Parkinson's disease. Excessive intake can cause anxiety, insomnia, and elevated heart rate.

น้ำหนักโมเลกุล

194.1900 g/mol

LogP

-0.10

TPSA

58.40 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Transplant Medicine Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Chronic Pain Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

Cn1c(=O)c2c(ncn2C)n(C)c1=O

InChI

InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3

Molecular Formula

C8H10N4O2

HBD / HBA

- / 3

พันธะที่หมุนได้

0

อะตอมหนัก

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A widely consumed methylxanthine stimulant that blocks adenosine receptors in the brain, promoting wakefulness and alertness. Medically, it is used in combination with analgesics for headaches, as a respiratory stimulant in premature infants, and is being studied for neuroprotective effects in conditions like Parkinson's disease. Excessive intake can cause anxiety, insomnia, and elevated heart rate.

Yes, Caffeine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL113. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2519. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Caffeine บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C8H10N4O2
คำพ้องความหมาย: 265

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.